Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Treatment

Resuscitative Endovascular Balloon Occlusion of the Aorta

Perioperative and Anesthetic Care

Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally invasive procedure performed during resuscitation of critically injured trauma patients, developed as a less invasive alternative to emergency thoracotomy with aortic cross clamping, to gain rapid control of non-compressible truncal or junctional hemorrhage. It is performed by achieving access to the common femoral artery and advancing a catheter within the aorta, then inflating an occluding balloon within the descending thoracic aorta or infrarenal abdominal aorta, which stanches downstream hemorrhage and improves cardiac index, cerebral perfusion and coronary perfusion. REBOA does not eliminate the need for definitive hemorrhage control and carries significant local and systemic ischemic risks, and while it has been successfully used in adult patients it has not yet been studied in children.

Facts
Classification
Status
Standard of Care 1
Resuscitative Endovascular Balloon Occlusion of the Aorta
Filter Results1 entry
Connections

Associated With

Treats

Shock, Conditions
Source Resuscitative endovascular balloon occlusion of the aorta (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
Resuscitative endovascular balloon occlusion of the aorta (Wikipedia)
  • https://en.wikipedia.org/wiki/Resuscitative_endovascular_balloon_occlusion_of_the_aorta, lead section
    Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally-invasive procedure performed during resuscitation of critically-injured trauma patients.
  • Treats: Shock, Ongoing investigation
    Current literature demonstrates a survival benefit of REBOA deployment in patients with severe hemorrhagic shock who do not require cardiopulmonary resuscitation (CPR).
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.